Intellia Therapeutics (NTLA) Stock Price, News & Analysis

Company Overview

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $9.33 to $9.68
• 50-Day Range: $6.99 to $9.67
• 52-Week Range: $5.90 to $28.18
• Volume: 2.74 million shs
• Average Volume: 2.92 million shs
• Market Capitalization: $971.58 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $33.37
• Consensus Rating: Moderate Buy

Intellia Therapeutics Stock Analysis - MarketRank™

Intellia Therapeutics scored higher than 92% of companies evaluated by MarketBeat, and ranked 83rd out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Intellia Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.65, and is based on 12 buy ratings, 6 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Intellia Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Intellia Therapeutics are expected to grow in the coming year, from ($5.07) to ($5.00) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Intellia Therapeutics is -1.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Intellia Therapeutics is -1.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Intellia Therapeutics has a P/B Ratio of 1.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

29.58% of the float of Intellia Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Intellia Therapeutics has a short interest ratio ("days to cover") of 6.7.

Change versus previous month

Short interest in Intellia Therapeutics has recently decreased by 5.93%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Intellia Therapeutics does not currently pay a dividend.

Dividend Growth

Intellia Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.67

Percentage of Shares Shorted

29.58% of the float of Intellia Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Intellia Therapeutics has a short interest ratio ("days to cover") of 6.7.

Change versus previous month

Short interest in Intellia Therapeutics has recently decreased by 5.93%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.4 / 5
• News Sentiment: 0.60

News Sentiment

Intellia Therapeutics has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Intellia Therapeutics this week, compared to 12 articles on an average week.

Search Interest

Only 27 people have searched for NTLA on MarketBeat in the last 30 days. This is a decrease of -16% compared to the previous 30 days.

MarketBeat Follows

Only 8 people have added Intellia Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Intellia Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,252.00 in company stock.

Percentage Held by Insiders

Only 3.10% of the stock of Intellia Therapeutics is held by insiders.

Percentage Held by Institutions

88.77% of the stock of Intellia Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NTLA Stock Analysis - Frequently Asked Questions

How have NTLA shares performed this year?

Intellia Therapeutics' stock was trading at $11.66 on January 1st, 2025. Since then, NTLA shares have decreased by 19.6% and is now trading at $9.38.
View the best growth stocks for 2025 here.

How were Intellia Therapeutics' earnings last quarter?

Intellia Therapeutics, Inc. (NASDAQ:NTLA) announced its quarterly earnings results on Thursday, May, 8th. The company reported ($1.10) earnings per share for the quarter, beating analysts' consensus estimates of ($1.26) by $0.16. The company's revenue was down 42.6% compared to the same quarter last year.
Read the conference call transcript.

When did Intellia Therapeutics IPO?

Intellia Therapeutics (NTLA) raised $85 million in an IPO on Friday, May 6th 2016. The company issued 5,000,000 shares at $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

How do I buy shares of Intellia Therapeutics?

Shares of NTLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Intellia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Intellia Therapeutics investors own include Chevron (CVX), Bristol Myers Squibb (BMY), Comcast (CMCSA), NVIDIA (NVDA), Charles Schwab (SCHW), Meta Platforms (META) and Edwards Lifesciences (EW).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 6/30/2025
• Next Earnings (Estimated): 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NTLA
• CIK: 1652130
• Web: www.intelliatx.com
• Phone: (857) 285-6200
• Fax: N/A
• Employees: 600
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $33.37
• High Stock Price Target: $68.00
• Low Stock Price Target: $7.00
• Potential Upside/Downside: +253.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.65
• Research Coverage: 20 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($5.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$519.02 million
• Net Margins: -1,154.10%
• Pretax Margin: -1,154.10%
• Return on Equity: -56.06%
• Return on Assets: -44.25%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.90
• Quick Ratio: 4.90

Sales & Book Value

• Annual Sales: $57.88 million
• Price / Sales: 16.90
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.56 per share
• Price / Book: 1.10

Miscellaneous

• Outstanding Shares: 103,580,000
• Free Float: 100,372,000
• Market Cap: $978.31 million
• Optionable: Optionable
• Beta: 2.15